GlobeNewswire

Record gold sales in the first quarter of 2018 high grade intercepts in the Guiro mine.

Dela

QUÉBEC CITY, April 11, 2018 (GLOBE NEWSWIRE) -- Komet Resources Inc. is delighted to have generated record gold sales of CA$1,354,000 in the first quarter of 2018, with a production cash cost of CA$1,038,000 for 27.5 kilos of gold from the Guiro mine located in Burkina Faso. This occurs after only two quarters of operation since the active start of the optimized process. The modernization of the Guiro plant was completed at the end of the second quarter 2017, with, among other things, the installation of an Acacia intensive leaching reactor, the establishment of an in-series triple gravity concentrator system, the refurbishment of a larger capacity ball mill with a larger capacity and the installation of a hydrocyclone to operate in closed circuit mode.

Recent Development at the Guiro Mine

The company has recently obtained the results of eight diamond drill holes conducted as part of the ongoing resource development of the Guiro mine in Burkina Faso (see table below). These include the following intersections: 0.68 m grading 180.50 g/t Au in borehole Gu2017dd05, 1.24 m grading 10.36 g/t Au in borehole Gu2017dd03 and 1.68 m grading 17.11 g/t Au in borehole Gu2017dd06. Gu2017dd04 borehole also intercepted mineralization below the 4-east level in the mine, 12.5 meters west to the previously known Gu2015dd16 hole of 4.3 m grading 9.2 g/t. The results of this survey confirm the continuity of the vein as defined in the published NI43-101 resource calculation. Mining planning will be in this way better defined. The experience in the Guiro mine allows us to give an influence of 12.5 meters on both sides of a hole. Future development in this area then allows us to plan more than 7,100 t at 7.79 g/t Auundiluted. The vein is still open at least toward the west and at depth.

Furthermore, the Gu2017dd06 borehole located between two previously mined stopes on level 2, confirms a hitherto unknown continuity due to inaccessibility. This will allow us to mine more than 1000 t at 17.11 g/t Au undiluted. This excellent result will be followed by verification of the upper vertical continuity of level 2 in this new mineralized horizon.

These results follow those on the west development of the mine, announced in the January 29, 2018, press release.

Ongoing development

Komet's team is pursuing development westward at level 3 to reach the western gold ore shoot and aims in particular to join, within 30 m, the strike of the previously announced Gu2015dd35 drill intersection (1.4 m at 31 g/t Au). The development to the east at level 4 is also underway to complete the 25 meters required to reach the mineralization mentioned above. At the junction of level 3, a total of 35 m out of the planned 70m north development is underway and will allow reaching a mineralized zone parallel to the Guiro vein, mentioned in historical works, and allow positioning of the new pneumatic drill (Bazooka) for exploration at depth of the Guiro vein.

Finally, at the main shaft intersection at level 4, the development of a gallery is in progress in order to reach the parallel vein named "Guiro Sud" which gave results by core drilling such as 57 cm at 10.62 g/t Au and 52 cm at 8.64 g/t Au. See the May 25, 2017, press release for more information.

Mr André Gagné, president and CEO stated: "The development of the Guiro mine, as well as the nearby discoveries, confirm the excellent gold potential within our reach. In addition, the good gold sales results of the first quarter confirm the company's vision: 'Discovering by producing!'"

Summary table of drilling results:

Hole number From (m) To (m) Interval (m) True width (m) Au (g/t)
Gu2017dd01 161.00 162.65 2.65 1.43 1.22
incl 161.00 161.75 0.75 0.65 2.09
incl 162.45 162.65 0.20 0.17 1.96
Gu2017dd03 167.20 168.44 1.24 1.07 10.36
incl 167.70 168.44 0.74 0.64 16.73
Gu2017dd04 154.38 159.00 4.62 4.00 1.47
incl 155.00 155.38 0.38 0.33 7.32
Gu2017dd05 58.82 60.65 1.83 1.58 67.58
incl 59.32 60.00 0.68 0.59 180.50
Gu2017dd06 73.95 75.63 1.68 1.45 17.11
incl 73.95 74.50 0.55 0.48 13.12
incl 74.50 74.88 0.38 0.33 7.05
incl 74.88 75.63 0.75 0.65 25.13

The samples assays reported were obtained by standard 30 grams fire-assaying-AA finish or gravimetric finish at the Company's mine site laboratory and by plating on 50 g aliquots with atomic absorption (ppm for gold) at BIGGS Global in Burkina Faso. Sampling and supervision of the works were carried out on the site by qualified technicians. Quality assurance and quality control program and interpretation of results are done by qualified geologists according to a 43-101 compliant QA / QC program and industry best practices, including the introduction of samples reference, sterile samples and duplicates for each batch of 20 samples analyzed.

More information about the corporation is available at: http://kometgold.com.

Investors relations and information: 
André Gagné, President and CEO / +1-581-300-1666 / a.gagne@kometgold.com / Skype: andregagne11

Relations Publiques Paradox Inc. / Carl Desjardins / +1-514-341-0408 / carldesjardins@paradox-pr.ca

Jacques Marchand, P.Eng. P.Geo., is the Qualified Person who has reviewed this news release and is responsible for the geological information presented herein.

Forward-Looking Statements

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. This press release contains statements that may constitute "forward-looking information" or "forward-looking statements" as set out within the context of security law. This forward-looking information is subject to many risks and uncertainties, some of which are beyond Komet's control. The actual results or conclusions may differ considerably from those that have been set out, or intimated, in this forward-looking information. There are many factors which may cause such disparity, especially the instability of metal market prices, the results of fluctuations in foreign currency exchange rates or in interest rates, poorly estimated resources, environmental risks (stricter regulations), unforeseen geological situations, unfavorable extraction conditions, political risks brought on by mining in developing countries, regulatory and governmental policy changes (laws and policies), failure to obtain the requisite permits and approvals from government bodies, or any other risk relating to mining and development. There is no guarantee that the circumstances anticipated in this forward-looking information will occur, or if they do occur, how they will benefit Komet. The forward-looking information is based on the estimates and opinions of Komet's management at the time of the publication of the information and Komet does not assume any obligation to make public updates or modifications to any of the forward-looking statements, whether as a result of new information, future events, or any other cause, except if it is required by securities laws.

A photo accompanying this announcement is available at http://resource.globenewswire.com/Resource/Download/0f952ff1-87ac-454d-a02f-9df5fbedf5db




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Komet Resources Inc. via Globenewswire

Om

GlobeNewswire



Följ GlobeNewswire

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från GlobeNewswire

Karolinska Development's portfolio company Aprea Therapeutics has received FDA Orphan Drug Designation and Fast Track Designation for APR-24616.4.2019 12:46:00 CESTPressmeddelande

STOCKHOLM, April 16, 2019. Karolinska Development's portfolio company Aprea Therapeutics has from FDA received an Orphan Drug Designation for APR-246 for the treatment of patients with Myelodysplastic Syndromes (MDS) having a TP53 mutation. In addition, FDA has also granted Fast Track Designation to APR-246 for treatment of MDS. Orphan Drug Designation is granted by the FDA Office of Orphan Products Development to advance the evaluation and development of safe and effective therapies for the treatment of rare diseases. The designation can provide development and commercial incentives for designated compounds and medicines, including eligibility for a seven-year period of market exclusivity in the U.S. after product approval, FDA assistance in clinical trial design, tax credits related to clinical trial expenses, and an exemption from FDA user fees. The FDA's Fast Track program facilitates the development of drugs intended to treat serious conditions and that have the potential to addre

Karolinska Developments portföljbolag Aprea Therapeutics har fått särläkemedelsstatus och snabbspårstatus från FDA för APR-24616.4.2019 12:46:00 CESTPressmeddelande

STOCKHOLM, SVERIGE - 16 april 2019. Karolinska Development AB meddelar idag att portföljbolaget Aprea Therapeutics har av FDA fått särläkemedelsstatus för APR-246 för behandling av patienter med TP53-muterad myelodysplastiskt syndrom (MDS). Dessutom ger FDA bolaget snabbspårstatus (Fast Track Designation), för APR-246 för behandling av MDS. Amerikanska läkemedelsverket, FDA, ger särläkemedelsstatus till läkemedelskandidater för att snabba på utvärderingen och utvecklingen av säkra och effektiva behandlingar av ovanliga sjukdomar. Särläkemedelsstatus ger företag både regulatoriska och kommersiella incitament genom att läkemedlet får marknadsexklusivitet på den amerikanska marknaden i sju år efter marknadsgodkännande samtidigt som företaget får stöd från FDA när det gäller designen av kliniska prövningar, skatteförmåner för kostnader kopplade till kliniska prövningar och avgiftsbefrielse från FDA. FDA:s snabbspår underlättar utvecklingen av läkemedel som är avsedda för att behandla allva

Bergman & Beving AB: Bergman & Beving förvärvar KGC10.4.2019 14:00:00 CESTPressmeddelande

Pressmeddelande Bergman & Beving förvärvar KGC Bergman & Beving har idag tecknat avtal om förvärv av samtliga aktier i KGC Verktyg & Maskiner AB. KGC, med säte i Älvsjö, har i mer än 60 år utvecklat och levererat kvalitetsverktyg och tillbehör för murning och plattsättning i det egna varumärket KGC. Bolaget omsätter cirka 80 MSEK per år, och har 24 anställda. "KGC är ett ledande varumärke med högt anseende hos murare och plattsättare och har en mycket stark ställning på den svenska marknaden", säger Pontus Boman, VD och koncernchef. Tillträde beräknas ske den 1 maj 2019 och förvärvet bedöms ha en marginellt positiv påverkan på Bergman & Bevings resultat per aktie under innevarande räkenskapsår. Stockholm den 10 april 2019 Bergman & Beving AB (publ) För ytterligare information kontakta: Pontus Boman, VD & Koncernchef, telefon 010-454 77 00 Peter Schön, CFO, telefon 070-339 89 99 Denna information lämnades, genom ovanstående kontaktpersoners försorg, för offentliggörande den 10 april 201

Bergman & Beving AB: Bergman & Beving acquires KGC10.4.2019 14:00:00 CESTPressmeddelande

Press release Bergman & Beving acquires KGC Bergman & Beving has today signed an agreement to acquire all shares in KGC Verktyg & Maskiner AB. KGC, based in Älvsjö, has for more than 60 years developed and delivered quality tools and accessories for bricklayers and tilers in its own brand KGC. The business has a turnover of approximately SEK 80 million per year, and has 24 employees. "KGC is a leading brand with high reputation among bricklayers and tilers and has a very strong position in the Swedish market," says Pontus Boman, President and CEO. The closing is taking effect on 1 May 2019 and the acquisition is expected to have a marginal positive impact on Bergman & Beving's earnings per share during the current fiscal year. Stockholm, 10 April 2019 Bergman & Beving AB (publ) For further information, please contact: Pontus Boman, President & CEO, Tel: +46 10 454 77 00 Peter Schön, CFO, Tel: +46 70 339 89 99 The information was submitted for publication, through the agency of the cont

Karolinska Development's portfolio company Aprea presents promising results with APR-246 in combination with immuno-oncology agents3.4.2019 14:00:00 CESTPressmeddelande

STOCKHOLM, April 3, 2019. Karolinska Development's portfolio company Aprea today presents results from studies with APR-246 in combination with immune checkpoint blockade. The results show that APR-246 can improve the effect of immuno-oncology agents. Karolinska Development portfolio company Aprea Therapeutics announced today the results of studies with APR-246 in combination with immune checkpoint blockade. The results were presented by researchers from Memorial Sloan Kettering Cancer Center at the 2019 AACR Annual Meeting in Atlanta. The studies collectively support a role for p53 activity in the tumor microenvironment and suggest that stabilization of the tumor suppressor protein, p53, by APR-246 can enhance anti-tumor immune response, particularly when combined with immuno-oncology agents. The studies characterized changes in the tumor immune microenvironment in melanoma and colorectal cancer in vivo models when treated with APR-246 and immuno-oncology agents, either alone or in co

Karolinska Development's portfolio company Aprea presents promising results with APR-246 in combination with immuno-oncology agents3.4.2019 14:00:00 CESTPressmeddelande

STOCKHOLM, April 3, 2019. Karolinska Development's portfolio company Aprea today presents results from studies with APR-246 in combination with immune checkpoint blockade. The results show that APR-246 can improve the effect of immuno-oncology agents. Karolinska Development portfolio company Aprea Therapeutics announced today the results of studies with APR-246 in combination with immune checkpoint blockade. The results were presented by researchers from Memorial Sloan Kettering Cancer Center at the 2019 AACR Annual Meeting in Atlanta. The studies collectively support a role for p53 activity in the tumor microenvironment and suggest that stabilization of the tumor suppressor protein, p53, by APR-246 can enhance anti-tumor immune response, particularly when combined with immuno-oncology agents. The studies characterized changes in the tumor immune microenvironment in melanoma and colorectal cancer in vivo models when treated with APR-246 and immuno-oncology agents, either alone or in co

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum